Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Lung Cancers

40 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    Melanoma
    Non Small Cell

    VICCMEL15137

    07/21/2015

    Characterizing the Cardiometabolic Implications of Immune Therapy

    Basic Science

    Lung
    Non Small Cell

    VICCTHO0547

    12/19/2005

    Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy (SPORE)

    Basic Science

    Lung
    Non Small Cell
    Small Cell

    VICCTHO0398

    12/04/2003

    Molecular Predictors of Lung Cancer Behavior. (SPORE)

    Basic Science

    Lung
    Non Small Cell

    VICCTHO0136

    05/01/2001

    Molecular Fingerprinting of Lung Cancer (SPORE)

    Other

    Lung

    VICCTHO15123

    05/20/2016

    The PERCEPTA Registry

    Other

    Lung

    VICCTHO15102

    01/05/2016

    Physical Activity Monitors for Valuable Endpoints in Malignant Pleural Effusions: the MOVE-MPE trial (pilot)

    Other

    Lung

    VICCTHO1555

    11/18/2015

    A Case-Control Study to Verify Diagnostic Performance of AminoIndex Technology

    Other

    Lung
    Non Small Cell

    ECOGTHOA151216

    09/17/2015

    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

    Other

    Lung

    VICCTHO1496

    04/03/2015

    Lung Cancer Screening Program at VICC: Correlative Study

    Other

    Lung
    Miscellaneous
    Small Cell

    VICCMD1494

    10/31/2014

    Specimen Collection under Clinical Protocol 06-C-0213 for Generation of Patient-Derived Models

    Treatment

    Lung
    Non Small Cell

    VICCTHO1614

    08/05/2016

    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

    Treatment

    Adrenocortical
    Lung
    Sarcoma
    Wilms / Other Kidney (Pediatrics)

    COGADVL1522

    08/02/2016

    A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

    Treatment

    Breast
    Lung
    Non Small Cell
    Ovarian
    Pancreatic

    VICCPHI1671

    08/02/2016

    A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

    Treatment

    Hematologic
    Leukemia
    Lung
    Miscellaneous
    Small Cell

    VICCHEMP1615

    07/21/2016

    A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

    Treatment

    Lung

    VICCTHO15129

    06/07/2016

    XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

    Treatment

    Lung
    Non Small Cell

    VICCTHO1625

    06/01/2016

    An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as First Line-Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    Lung
    Small Cell

    VICCTHO15117

    05/19/2016

    A Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Carcinoma (TRINITY)

    Treatment

    Lung
    Non Small Cell

    ECOGTHOS1403

    04/26/2016

    A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)

    Treatment

    Colon
    Head/Neck
    Liver
    Lung
    Miscellaneous
    Neuro-Oncology
    Rectal
    Sarcoma
    Thyroid

    VICCMD15110

    04/05/2016

    A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

    Treatment

    Lung
    Small Cell

    VICCTHO1595

    03/25/2016

    An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy

    Treatment

    Colon
    Head/Neck
    Lung
    Lymphoma
    Melanoma
    Non Small Cell
    Ovarian
    Rectal

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    Lung
    Non Small Cell

    VICCTHO1573

    02/01/2016

    An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    Colon
    Esophageal
    Head/Neck
    Lung
    Non Small Cell
    Rectal

    VICCPHI1598

    12/10/2015

    A Phase 1 Multi Arm Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 with seribantumab (MM-121), istiratumab (MM-141), or trametinib in biomarker-selected cancer patients

    Treatment

    Bladder
    Breast
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Gynecologic
    Head/Neck
    Kidney (Renal Cell)
    Lung
    Melanoma
    Non Small Cell
    Pancreatic
    Rectal
    Urologic
    Uterine

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    Lung
    Non Small Cell

    VICCTHO1521

    10/16/2015

    A Phase III, Open-Label, Randomized, Study of MPDL3280A (Anti-PDL1 Antibody) Compared with Gemcitabine + Cisplatin or CARBOPLATIN for PD-L1-Selected, Chemotherapy Naive Patients with Stage IV Squamous Non-Small Cell Lung Cancer

    Treatment

    Lung

    VICCTHO1519

    10/07/2015

    A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti−PDL1 Antibody) Compared with Cisplatin or Carboplatin+Pemetrexed for PD-L1−Selected Chemotherapy Naive Patients with Stage Iv Non-Squamous Non−Small Cell Lung Cancer

    Treatment

    Lung
    Non Small Cell

    ECOGTHOE4512

    09/15/2015

    A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

    Treatment

    Breast
    Lung
    Pancreatic

    VICCPHI1528

    07/22/2015

    A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors

    Treatment

    Lung
    Small Cell

    VICCTHO1510

    07/09/2015

    A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Treatment

    Lung
    Non Small Cell

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

    Treatment

    Lung
    Non Small Cell

    VICCTHO1443

    03/11/2015

    A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    Lung

    CTSUTHOS1400

    01/20/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer Lung-MAP Study Targeted Treatment for Advanced Squamous Cell Lung Cancer

    Treatment

    Lung
    Non Small Cell

    VICCTHO1478

    11/14/2014

    A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

    Treatment

    Lung

    ECOGTHO2511-M

    11/04/2014

    Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

    Treatment

    Lung

    THOMK3475-024-M

    08/05/2014

    MK3475-024 A Randomized Open-Label Phase III Trial of Pembrolizumab versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer

    Treatment

    Lung
    Non Small Cell

    VICCTHN1244

    07/25/2012

    Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors

    Treatment

    Non Small Cell

    ECOGTHO5508-M

    02/09/2011

    Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

    Treatment

    Lung

    ECOGTHO4508-M

    12/07/2010

    Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy

    Treatment

    Lung

    CTSUTHOC30607-M

    02/17/2010

    ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

    Treatment

    Non Small Cell

    ECOGTHOE1505-M

    07/27/2007

    A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)


    Print this page for your doctor